Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2004

View Archived Issues

Statins improve outcomes in heart failure patients

Tamsulosin improves symptoms and quality of life in patients with CP/CPPS

Antiobesity drug effective against prostate cancer

11beta-Hydroxysteroid dehydrogenase inhibitor improves metabolic syndrome features

Preference for tadalafil among patients with erectile dysfunction

Aletheon acquires Pretarget intellectual property from NeoRx

NeoRx acquires rights to AMD-473 from AnorMED

SkyePharma and Medeus Pharma enter European DepoMorphine agreement

Schering AG to transfer oxybutynin incontinence ring to Barr

Array BioPharma and Takeda enter new drug discovery collaboration

Enrollment under way in phase III Periostat MR study for adult periodontitis

MediGene extends clinical development of Polyphenon E to actinic keratosis

Nycomed to develop and commercialize Oxygent in Europe

Adventrx enters definitive agreement for sale of common stock

ActivX to characterize activity of Gilead compounds

Novel histamine H3 antagonists and their use as antiobesity agents

Chiron researchers claim new pyrrole-based GSK-3 inhibitors

New gossypol analogues and their use in cancer therapy reported by CNRS

Merck KGaA team presents novel inhibitors of factor Xa and other coagulation factors

Novel small molecule tubulin inhibitor by Zentaris

Karo Bio scientists identify new thyroid receptor-beta agonists

New P-selectin antagonists and their use covered by Yamanouchi patent

Enhanced tumor cytotoxicity with novel DNA-PK inhibitor

New glucocorticoid receptor modulators discovered at Boehringer Ingelheim

New MTP inhibitors in early development at Janssen

Novel Bcl-XL antagonist effective against chemoresistant cancers in vivo

Phase II study of Puricase for severe gout begins

Ipsen enters into licensing agreement for Auxilium's Testim

Indevus and Pliva enter U.S. copromotion deal for Sanctura

Japanese launch for Viread

Vela licenses late-stage molecule for depression from Otsuka

FASgen receives NCI grant to support study of FAS inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...